Abstract: Disclosed herein is a kit to produce a personalized vaccine based on autologous dendritic cells. The kit contains all the materials, reagents and information necessary to produce a dose of live dendritic cell vaccine against a pathogen organism, part of a pathogen organism, a toxin, a venom, a structure obtained by recombinant method or chemical synthesis.

Abstract: Disclosed herein are compositions comprising complexes of cyclodextrins and lipid-modified stem cell proteins. Also disclosed are topical compositions the complexes. Methods of using the compositions for the therapeutic purposes are also disclosed as well as methods of producing the compositions.

Abstract: The present specification provides methods for augmenting the antigenic content, especially of tumor-associated antigens (TAA), and immunogenicity of cancer cells; methods for enhancing cross-presentation in dendritic cells, compositions comprising such manipulated cells derived from single cancer patients; and methods of using those compositions as a personal immunotherapeutic product to treat the donor patient's cancer.

Abstract: Disclosed herein are methods for selecting cancer patients for autologous cancer vaccine therapy and methods for predicting survival of cancer patients after autologous cancer vaccine therapy comprising, measuring the level of soluble programmed cell death protein-1 (sPD-1) in the blood of the patient.

Abstract: Disclosed herein are compositions comprising complexes of cyclodextrins and lipid-modified stem cell proteins. Also disclosed are topical compositions the complexes. Methods of using the compositions for the therapeutic purposes are also disclosed as well as methods of producing the compositions.

Abstract: Disclosed herein are compositions comprising complexes of cyclodextrins and lipid-modified stem cell proteins. Also disclosed are topical compositions the complexes. Methods of using the compositions for the therapeutic purposes are also disclosed as well as methods of producing the compositions.

Abstract: Disclosed herein are cosmetic compositions containing stem cell secreted proteins that, in a cosmetic amount, are effective to enhance appearance of photo-damaged, or aged, skin.

Abstract: The present specification provides methods for augmenting the antigenic content, especially of tumor-associated antigens (TAA), and immunogenicity of cancer cells; methods for enhancing cross-presentation in dendritic cells, compositions comprising such manipulated cells derived from single cancer patients; and methods of using those compositions as a personal immunotherapeutic product to treat the donor patient's cancer.

Abstract: Disclosed herein are compositions comprising complexes of cyclodextrins and lipid-modified stem cell proteins. Also disclosed are topical compositions the complexes. Methods of using the compositions for the therapeutic purposes are also disclosed as well as methods of producing the compositions.

Abstract: Disclosed herein are cosmetic or dermatologic compositions containing stem cell secreted proteins and fetuin that, in an effective amount, enhance appearance of photo-damaged, or aged, skin.

Abstract: The disclosure provides cancer stem cells, for use in stimulating immune response against a cancer, such as ovarian carcinoma. Methods for preparing and purifying the cancer stem cells are provided.

Abstract: The present disclosure provides reagents and methods for stimulating an immune response against an antigen associated with glioblastoma multiforme.

Abstract: The disclosure provides cancer stem cells, for use in stimulating immune response against a cancer, such as colon carcinoma (CC). Methods for preparing and purifying the cancer stem cells are provided.

Abstract: The disclosure provides cancer stem cells, for use in stimulating immune response against a cancer, such as hepatocellular carcinoma (HCC). Methods for preparing and purifying the cancer stem cells are provided.

Abstract: A bioreactor with a removable reactor core having internal growth chambers, a first end with an inlet upstream from said core; a second end downstream with an outlet from said core; and, a pumping means to provide media flow, is disclosed.

Abstract: Aspects of implementations wherein reductions in contamination in transplantation cell population are disclosed herein, including incubating a suspended population of live cells in a culture medium with a substrate having surface that promotes cell to cell adhesion. During the process, the incubating is in absence of substantial mechanical disturbance of the culture medium and cells are in the culture medium for a predetermined period of time. A resulting population of cells which is relatively reduced or eliminated in contaminants is taught. Said population of cells may be collectable by centrifugation and is separable from said contaminants by centrifugation.

Abstract: The invention provides media formulations. A complete media formulation of the invention includes, for example, the following components: albumin, an iron carrier, glutamine, a glycosidase or hydrolase, fibroblast growth factor (FGF), a salt or mineral, and essential amino acids at an osmolarity of about 220-330 mOsm/Liter.

Abstract: The invention provides methods for producing a culture of cardiomyocytes and cultures of cardiomyocytes. Exemplary methods of producing and cultures of cardiomyocytes include a population of cells including cells having spontaneous and periodic electrical activity, and/or including nodal, sino-atrial or pacemaker cells; immature cardiomyocytes (cardiomyoblasts); mature contractile cardiomyocytes; or a mixed population of two or more of such cells.

Abstract: The invention provides methods for producing a culture of cardiomyocytes and cultures of cardiomyocytes. Exemplary methods of producing and cultures of cardiomyocytes include a population of cells including cells having spontaneous and periodic electrical activity, and/or including nodal, sino-atrial or pacemaker cells; immature cardiomyocytes (cardiomyoblasts); mature contractile cardiomyocytes; or a mixed population of two or more of such cells.

Abstract: The invention provides media formulations. A complete media formulation of the invention includes, for example, the following components: albumin, an iron carrier, glutamine, a glycosidase or hydrolase, fibroblast growth factor (FGF), a salt or mineral, and essential amino acids at an osmolarity of about 220-330 mOsm/Liter.